<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tuberculous pleural effusion</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tuberculous pleural effusion</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tuberculous pleural effusion</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amit Chopra, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John T Huggins, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Bernardo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tuberculous pleural effusion is the second most common form of extrapulmonary tuberculosis (TB) (after lymphatic involvement) and is the most common cause of pleural effusion in areas where TB is endemic [<a href="#rid1">1-5</a>]. Tuberculous pleural effusion is synonymous with the term tuberculous pleurisy.</p><p>Issues related to the evaluation and management of tuberculous pleural effusions will be reviewed here. Issues related to pulmonary TB are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a> and  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"</a>.)</p><p class="headingAnchor" id="H545496973"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Tuberculous pleural effusions can occur in association with reactivation disease or primary tuberculosis [<a href="#rid4">4,6-9</a>]. In adults, most often they occur due to reactivation disease [<a href="#rid7">7,8</a>]; in children, most often they occur in the setting of primary disease [<a href="#rid9">9</a>].</p><p>Development of tuberculous pleural effusion may occur as a result of delayed hypersensitivity reaction to mycobacteria or mycobacterial antigens in the pleural space in sensitized individuals [<a href="#rid10">10</a>] or by rupture of a subpleural focus of pulmonary disease into the pleural space [<a href="#rid11">11</a>].</p><p>In patients without apparent parenchymal involvement, pleural disease may develop via hematogenous spread following primary infection.</p><p>Tuberculous empyema can develop via extension of infection from thoracic lymph nodes or a subdiaphragmatic focus, via hematogenous spread, or in the setting of pneumothorax.</p><p class="headingAnchor" id="H3576050"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H2158338198"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>Patients with tuberculous pleural effusion usually have an acute febrile illness with nonproductive cough (94 percent) and pleuritic chest pain (78 percent) [<a href="#rid12">12</a>]. Night sweats, chills, weakness, dyspnea, and weight loss can also occur. The peripheral white blood cell count is typically normal [<a href="#rid12">12</a>].</p><p>Tuberculous pleural effusions are usually unilateral, small to moderate in size, and self-limited [<a href="#rid6">6</a>]. In patients without human immunodeficiency virus (HIV) infection, tuberculous pleural effusions occur slightly more frequently on the right side than the left (55 versus 45 percent) [<a href="#rid13">13,14</a>] and occupy less than two-thirds of the hemithorax in 82 percent of cases [<a href="#rid13">13</a>]. In patients with HIV infection, tuberculous pleural effusions are equally distributed on the left and right; a miliary pattern is observed in 7 to 10 percent of cases. Adenopathy occurs in 5 to 18 percent of cases [<a href="#rid15">15</a>].</p><p>Tuberculous pleural effusion can progress to tuberculous empyema, characterized by purulent fluid containing numerous organisms. Tuberculous empyema is often associated with a thickened, scarred, and calcified pleura (<a class="graphic graphic_diagnosticimage graphicRef106792" href="/z/d/graphic/106792.html" rel="external">image 1</a>) [<a href="#rid16">16,17</a>].</p><p>Patients with HIV infection are at increased risk for progression from latent tuberculosis (TB) infection to active TB disease, and pleural involvement is common in the presence of HIV coinfection [<a href="#rid14">14,18,19</a>]. Clinical manifestations of tuberculous pleural effusion in the setting of HIV infection include fever (85 percent), cough (77 percent), chest pain (36 percent), dyspnea (23 percent), and weight loss &gt;2 kg (74 percent) [<a href="#rid20">20-22</a>]. Additional signs and symptoms such as night sweats, diarrhea, hepatosplenomegaly, and lymphadenopathy are also more common in patients with HIV infection.</p><p class="headingAnchor" id="H2044476623"><span class="h2">Radiographic findings</span><span class="headingEndMark"> — </span>Chest radiography demonstrates parenchymal disease in association with pleural effusion in up to 50 percent of patients without HIV infection [<a href="#rid4">4</a>] and 73 percent of patients with HIV infection [<a href="#rid21">21,22</a>]. Among patients without HIV infection, the upper lobe is involved in approximately 75 percent of cases (suggestive of reactivation TB), and the lower lobe is involved in approximately 25 percent of cases (suggesting primary disease). Among patients with HIV infection, in contrast, parenchymal disease occurs most often in the lower lobe (75 percent) [<a href="#rid15">15</a>]. The pleural effusion virtually always occurs on the same side as the parenchymal infiltrate [<a href="#rid12">12</a>].</p><p>Computed tomography is more sensitive than chest radiography; it demonstrates parenchymal disease in over 80 percent of cases, supporting the theory of spread to the pleura from a subpleural focus (<a class="graphic graphic_diagnosticimage graphicRef63772" href="/z/d/graphic/63772.html" rel="external">image 2</a>) [<a href="#rid23">23</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p class="headingAnchor" id="H948821092"><span class="h2">Complications</span></p><p class="headingAnchor" id="H2389754269"><span class="h3">Tuberculosis empyema</span><span class="headingEndMark"> — </span>TB empyema can develop as a complication of tuberculous pleuritis or pulmonary TB [<a href="#rid17">17</a>]. TB empyema is characterized by chronic mycobacterial infection of the pleural space [<a href="#rid17">17</a>]. In patients with long-standing TB empyema, the pleura is thickened and may calcify. In patients with TB empyema, the pleural effusion is neutrophilic predominant with high mycobacterial burden [<a href="#rid17">17</a>]. The diagnostic yield of acid-fast bacilli smear and culture is higher for TB empyema than for tuberculous pleural effusion without empyema [<a href="#rid24">24</a>]. Invasive surgery is often required to remove the focus of infection and prevention of fibrothorax [<a href="#rid25">25,26</a>].</p><p class="headingAnchor" id="H3987332974"><span class="h3">Pseudochylothorax</span><span class="headingEndMark"> — </span>Tuberculous pleural effusion is the most common cause of pseudochylothorax (cholesterol effusion) worldwide. (See  <a class="medical medical_review" href="/z/d/html/16317.html" rel="external">"Clinical presentation, diagnosis, and management of cholesterol pleural effusions"</a>.)</p><p class="headingAnchor" id="H3694852971"><span class="h3">Residual pleural thickening</span><span class="headingEndMark"> — </span>Residual pleural thickening can occur in up to 50 percent of patients [<a href="#rid22">22,27-31</a>]. In one study including 56 patients without HIV infection with tuberculous pleural effusion, residual pleural thickening following completion of medical therapy was more likely among those with initial pleural fluid analysis notable for relatively low pH, low glucose concentration, high lysozyme concentration, and high tumor necrosis factor-alpha concentration [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H3577153"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H2019966297"><span class="h2">Clinical approach</span><span class="headingEndMark"> — </span>The diagnosis of tuberculous pleural effusion should be suspected in patients with pleural effusion and relevant epidemiologic risk factors for tuberculosis (TB) infection (these include current or prior history of TB infection, known or possible TB exposure, and/or past or present residence in or travel to an area where TB is endemic). (See  <a class="medical medical_review" href="/z/d/html/8018.html" rel="external">"Epidemiology of tuberculosis"</a>.)</p><p>The diagnosis of tuberculous pleural effusion may be definitively established via demonstration of <em>Mycobacterium tuberculosis</em> in pleural fluid or a pleural biopsy specimen [<a href="#rid1">1,6</a>].</p><p>It is reasonable to make a presumptive diagnosis of TB without pathologic confirmation in the following scenarios:</p><p class="bulletIndent1"><span class="glyph">●</span>In a patient with an established diagnosis of pulmonary TB without signs/symptoms that raise suspicion for an alternative cause for pleural effusion (such as malignancy) (see <a class="local">'Differential diagnosis'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the setting of high clinical suspicion for TB, pleural fluid analysis with lymphocytic-to-neutrophil ratio &gt;0.75 and adenosine deaminase (ADA) &gt;40 units/L, or by demonstration of one or more caseating granulomas on pleural biopsy [<a href="#rid1">1,2,33,34</a>] (see <a class="local">'Pleural fluid analysis'</a> below and <a class="local">'Pleural biopsy'</a> below)</p><p></p><p>The initial evaluation of patients with suspected tuberculous pleural effusion should include diagnostic evaluation for pulmonary TB, beginning with sputum collection for smear/culture for acid-fast bacilli and for nucleic acid amplification (NAA) testing. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p>Diagnostic thoracentesis is warranted in the following circumstances (see <a class="local">'Pleural fluid analysis'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Suspected tuberculous pleural effusion in the absence of an established diagnosis of pulmonary TB (via sputum or other studies)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis of pulmonary TB established (via sputum or other studies) but additional etiology for pleural effusion (such as malignancy) suspected clinically</p><p></p><p>Pleural biopsy is warranted if the above circumstances persist and the pleural fluid ADA level is &lt;40 units/L and/or pleural fluid evaluation is otherwise not diagnostic; the yield for mycobacterial culture of pleural tissue is higher than for pleural fluid. Given the low microbiologic-confirmatory yield from pleural fluid alone and the length of time that may be required for growth in culture (up to eight weeks), pursuit of pleural biopsy early in the diagnostic evaluation may be warranted, especially in complex patients with broad differential diagnosis or suspected drug resistance. (See <a class="local">'Pleural biopsy'</a> below.)</p><p>Patients with tuberculous pleural effusion should undergo diagnostic testing for HIV infection. (See  <a class="medical medical_review" href="/z/d/html/86984.html" rel="external">"Acute and early HIV infection: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H3577801"><span class="h2">Pleural fluid analysis</span><span class="headingEndMark"> — </span>Indications for thoracentesis are described above. (See <a class="local">'Clinical approach'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> − Pleural fluid should be sent for the following studies: cell count, protein, glucose, pH, lactate dehydrogenase (LDH), acid-fast bacilli (AFB) smear and culture, Gram stain and culture, and ADA level (if the effusion is lymphocyte predominant) [<a href="#rid1">1</a>]. NAA testing for <em>M. tuberculosis</em> in pleural fluid has not been approved by the US Food and Drug Administration (FDA) in the United States. Confirmation of the diagnosis of TB requires growth in culture, which may take up to eight weeks. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Characteristics of tuberculous pleural effusion</strong> − Tuberculous pleural effusion is an exudative, lymphocyte-predominant pleural effusion, usually with the following characteristics [<a href="#rid13">13,20,21,35</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Color – Straw colored [<a href="#rid36">36</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Protein concentration – &gt;3.0 g/dL (30 g/L) [<a href="#rid12">12,37</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>LDH – Elevated in approximately 75 percent of cases, with levels commonly exceeding 500 international units/L [<a href="#rid4">4,12,13,37</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>pH – Less than 7.40 in most cases; pH &lt;7.30 is observed in about 20 percent of cases</p><p class="bulletIndent2"><span class="glyph">•</span>Glucose – Usually between 60 and 100 mg/dL (3.3 and 5.6 mmol/L); glucose levels below 50 mg/dL (2.8 mmol/L) are observed in 7 to 20 percent of effusions, and extremely low glucose concentrations (&lt;30 mg/dL [1.7 mmol/L]) can occur occasionally [<a href="#rid12">12,37</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pleural fluid cell count</strong> − The pleural fluid nucleated cell count is usually between 1000 and 6000 cells/mm<sup>3</sup> [<a href="#rid13">13</a>]. It is lymphocyte predominant in 60 to 90 percent of cases and neutrophil predominant in the remaining cases [<a href="#rid4">4,12,37</a>]. Neutrophils predominate in the first few days following onset of pleural inflammation; lymphocytes predominate thereafter [<a href="#rid36">36,38,39</a>]. There is no significant correlation between the peripheral CD4 count and the pleural fluid cell count or composition [<a href="#rid22">22,35</a>]. The pleural fluid rarely contains more than 5 percent mesothelial cells on the cell differential count; the laboratory may report "many mesothelial cells" without providing a percentage. Eosinophils are uncommon; the presence of more than 10 percent eosinophils usually excludes the diagnosis of tuberculous pleural effusion unless the patient had a pneumothorax or hemothorax near the time of pleural fluid analysis [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/6704.html" rel="external">"Pleural fluid eosinophilia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pleural fluid ADA level</strong> − The pleural fluid ADA level may be useful to establish a diagnosis of tuberculous pleural effusion, even when AFB smear and culture are negative [<a href="#rid1">1,2,5</a>]. Elevated pleural fluid ADA levels can occur in other conditions besides TB infection, including malignancy. Some studies suggest that an ADA level &gt;45 to 60 units/L is 100 percent sensitive and up to 97 percent specific for tuberculous pleural effusion [<a href="#rid13">13,35,41-46</a>]. </p><p></p><p class="bulletIndent1">The diagnostic performance of ADA level can be affected by the local prevalence of TB. In low prevalence regions, its main advantage is in its negative predictive value. As an example, in one study from South London between 2009 to 2015, patients with lymphocytic predominant pleural effusion and pleural fluid ADA level &lt;40 U/L were unlikely to have tuberculous pleural effusion (negative predictive value 98 percent) [<a href="#rid47">47</a>]. However, in high prevalence regions, tuberculous pleural effusion cannot be excluded in the presence of lymphocytic predominant pleural effusion by any level of ADA in pleural fluid [<a href="#rid48">48</a>]. The diagnostic probability of tuberculous pleural effusion is very high in patients with pleural fluid ADA levels &gt;70 U/L. However, if the ADA level is indeterminate (40 to 70 U/L), further interventions depend upon the pretest probability of TB [<a href="#rid48">48</a>]. Patients with lymphocytic predominant pleural effusion and a low ADA level (&lt;40 U/L) should be considered for a pleural biopsy to assess for tubercular pleural effusion or an alternative cause. </p><p></p><p class="bulletIndent1">HIV status can affect the diagnostic accuracy of pleural fluid ADA levels. Among patients with HIV infection, one study noted an ADA cutoff level of 60 units/L in patients with HIV infection and provided a sensitivity and specificity of 95 and 96 percent, respectively [<a href="#rid35">35,49,50</a>]. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1">Elevated pleural fluid ADA levels can occur in other conditions besides TB infection; these include bacterial empyema, mesothelioma, lung cancer, lymphoma, parapneumonic effusion, and hematologic malignancies. Most assays report only the total ADA level and do not distinguish between the two principal isoenzymes, ADA-1 and ADA-2. ADA-2 is increased in tuberculous effusions, while ADA-1 is increased in other conditions [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pleural fluid AFB culture</strong> − Pleural fluid AFB cultures are positive in fewer than 20 to 30 percent of patients without HIV infection [<a href="#rid6">6</a>]. Patients with HIV infection may present with a greater burden of organisms than patients without HIV infection; in patients with HIV infection with CD4 count less than 100 cells/mm<sup>3</sup>, AFB cultures are positive in approximately 50 percent of cases [<a href="#rid52">52-54</a>]. Tuberculous empyema fluid is grossly purulent and usually AFB smear and culture positive [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of NAA assays</strong> − NAA assays approved by the FDA for use with sputum are not approved for use with pleural fluid in the United States. Some laboratories perform NAA testing of pleural fluid as a laboratory-validated, "off-label" application of the testing platform; in such cases, the test characteristics should be reviewed with the laboratory before a clinical sample is submitted. NAA techniques for evaluation of tuberculous pleural effusion in patients without HIV infection appear to have high specificity but relatively low sensitivity [<a href="#rid55">55,56</a>]. In one meta-analysis including 18 studies, the sensitivity and specificity for the Xpert MTB/RIF assay (compared with culture) in pleural fluid were 46 and 99 percent, respectively [<a href="#rid56">56</a>]. Among patients with HIV infection, it is reasonable to anticipate that the higher microbial burden in the pleural fluid is likely to be associated with a higher sensitivity of NAA assays (compared with patients without HIV infection); data are limited. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other assays</strong> − Other assays that may be useful for supporting or excluding a diagnosis of tuberculous pleural effusion include pleural fluid interferon-gamma concentration and pleural fluid lysozyme concentrations [<a href="#rid5">5,43,46,57-61</a>]. However, these tests have not been approved by the FDA for this purpose and they do not have a role in routine evaluation of suspected tuberculous pleural effusion.</p><p></p><p class="headingAnchor" id="H5532816"><span class="h2">Pleural biopsy</span><span class="headingEndMark"> — </span>Indications for pleural biopsy are described above. (See <a class="local">'Clinical approach'</a> above.)</p><p>Pleural biopsy should be sent for AFB smear and culture as well as histopathological evaluation. Positive culture allows organism identification and drug susceptibility testing. Histopathology may demonstrate granulomas and/or acid-fast bacilli. The presence of caseating (necrotizing) granulomas on histologic examination is virtually diagnostic of tuberculous pleural effusion. Noncaseating granulomas may also be observed; occasionally, these can be seen in other disorders as well. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>In patients without HIV infection, the diagnostic yield of pleural biopsy tissue is 60 to 95 percent [<a href="#rid6">6,36,62,63</a>]. Culture of pleural biopsy material is positive in 40 to 80 percent of cases, and histology demonstrates granulomas in 50 to 97 percent of cases [<a href="#rid6">6</a>]. In patients with HIV infection, the diagnostic yield of pleural biopsy tissue is 44 to 69 percent [<a href="#rid21">21,22</a>]. Granulomas are observed less frequently than in patients without HIV infection but may be seen [<a href="#rid21">21,22,54</a>].</p><p>Pleural tissue can be obtained via thoracoscopy or closed percutaneous needle biopsy. The sensitivities of these techniques are comparable with each other when pleural fluid ADA and lymphocyte to neutrophil ratios were added to the needle biopsy analysis; needle biopsy is generally preferred in areas where tuberculous pleuritis is common [<a href="#rid64">64,65</a>]. (See  <a class="medical medical_review" href="/z/d/html/6707.html" rel="external">"Diagnostic evaluation of the hemodynamically stable adult with a pleural effusion", section on 'Pleural biopsy'</a>.)</p><p class="headingAnchor" id="H8017296"><span class="h2">Additional evaluation</span><span class="headingEndMark"> — </span>In addition to pleural evaluation, routine diagnostic evaluation for pulmonary TB should also be pursued; this is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p>Sputum culture is positive in 20 to 50 percent of patients without HIV infection with pleural effusion; positive sputum culture is more likely in the setting of concomitant parenchymal disease [<a href="#rid4">4,11,12,37,66</a>]. In one report of 70 patients without HIV infection with tuberculous pleural effusions, sputum culture was positive in 89 percent of patients with parenchymal changes but only 11 percent of patients without parenchymal changes [<a href="#rid66">66</a>]. The yields for induced sputum and pleural biopsy were 52 and 62 percent, respectively [<a href="#rid66">66</a>]. Among patients with HIV infection, the sputum smear or culture is positive in one-third to one-half of cases [<a href="#rid21">21,22,54</a>] and may even be positive when the chest radiograph is negative [<a href="#rid66">66</a>].</p><p><a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">Tuberculin skin test</a> (TST) and interferon-gamma release assays (IGRAs) cannot distinguish between latent TB infection and active TB disease [<a href="#rid67">67</a>]. Older series reported almost uniformly positive TST results in patients with tuberculous pleural effusions; subsequent reports have observed false-negative tests in 7 to 30 percent of patients [<a href="#rid4">4,12</a>]. Many patients without HIV infection with tuberculous pleural effusion and an initially negative TST have a positive TST if retested two months later. One possible explanation for the initial negative TST is suppression of sensitized T cells in the peripheral circulation and skin by circulating adherent mononuclear cells (chiefly monocytes, not classic CD8 suppressor cells); these monocytes are known to suppress antigen-induced lymphocyte blastogenesis and the production of interleukin 2. Among patients with HIV infection with tuberculous pleural effusion, the TST is positive in 20 to 64 percent of cases [<a href="#rid20">20-22,54</a>].</p><p>The use of IGRAs on pleural fluid for the diagnosis of tuberculous pleural effusion lacks sufficient sensitivity and specificity for diagnostic use. One meta-analysis evaluating the diagnostic performance of blood and pleural fluid–based IGRAs in tuberculous pleural effusion noted pooled sensitivity and specificity for blood assays of 77 percent (95% CI 0.71 to 0.83) and 71 percent (95% CI 0.65 to 0.76), respectively; the pooled sensitivity and specificity for the pleural fluid assays were 72 percent (95% CI 0.55 to 0.84) and 78 percent (95% CI 0.65 to 0.87), respectively [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/15352.html" rel="external">"Use of interferon-gamma release assays for diagnosis of tuberculosis infection (tuberculosis screening) in adults"</a>.)</p><p>The sensitivity of the Xpert MTB/RIF Ultra assay for diagnosis of pleural TB is poor. In a cohort study including 317 patients with suspected pleural TB, the sensitivity of Xpert MTB/RIF Ultra was poor (44 percent); however, the assay performance was superior to culture (26 percent) and smear (1.4 percent) [<a href="#rid69">69</a>]. The sensitivity of the assay was driven by individuals who were smear positive; such is clearly driven by organism burden when compared with those who were smear-negative individuals.</p><p class="headingAnchor" id="H4053558263"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis for tuberculous pleural effusion includes other causes of exudative pleural effusion (<a class="graphic graphic_table graphicRef54055" href="/z/d/graphic/54055.html" rel="external">table 1</a>) [<a href="#rid70">70</a>]. Many may be suspected clinically, and some can be confirmed by pleural fluid analysis or biopsy (<a class="graphic graphic_table graphicRef50027" href="/z/d/graphic/50027.html" rel="external">table 2</a>). In addition, alternative causes of pleural effusions may coexist in patients with pulmonary tuberculosis.</p><p>The following are the common causes of nontuberculous pleural effusions:</p><p class="bulletIndent1"><span class="glyph">●</span>Malignant pleural effusion – The diagnosis of malignant pleural effusion may be established via pleural fluid cytology and/or pleural biopsy. (See  <a class="medical medical_review" href="/z/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congestive heart failure – The diagnosis of congestive heart failure may be established via echocardiography and other studies. (See  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parapneumonic effusion or empyema – Parapneumonic effusion or empyema may be caused by bacterial infection; the diagnosis may be established by bacterial culture. (See  <a class="medical medical_review" href="/z/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sarcoidosis-associated pleural effusion (SAPE) – Pleural fluid analysis in patients with SAPE can be indistinguishable from tuberculous pleural effusion. Tuberculous pleural effusion can be differentiated from SAPE by clinical features and microbiologic data [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a>.) </p><p></p><p>The differential diagnosis of caseating (necrotizing) granulomas includes fungal infection such as histoplasmosis and cryptococcus. (See  <a class="medical medical_review" href="/z/d/html/2451.html" rel="external">"Diagnosis and treatment of pulmonary histoplasmosis"</a> and  <a class="medical medical_review" href="/z/d/html/2421.html" rel="external">"Cryptococcus neoformans infection outside the central nervous system"</a>.)</p><p>The differential diagnosis of noncaseating granulomas includes sarcoidosis, rheumatoid pleuritis, and berylliosis. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">"Overview of pleuropulmonary diseases associated with rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/4367.html" rel="external">"Chronic beryllium disease (berylliosis)"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Management of tuberculous pleural effusion consists of antituberculous therapy; pleural drainage is usually reserved for patients with severe symptoms.</p><p class="headingAnchor" id="H4032127835"><span class="h2">Antituberculous therapy</span><span class="headingEndMark"> — </span>The approach to antituberculous therapy for treatment of tuberculous pleural effusion is the same as the approach to treatment of active pulmonary tuberculosis (TB); this is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a> and  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"</a>.)</p><p>In the absence of definitive diagnosis, presumptive antituberculous therapy is warranted for patients with epidemiologic risk factors for TB infection and supportive diagnostic studies in the absence of an alternative diagnosis. As an example, this includes patients with TB risk factors and/or a positive TST or interferon-gamma release assay, exudative pleural effusion with lymphocyte predominance, elevated pleural ADA level (&gt;40 units/L), low pleural fluid glucose level, negative pleural fluid cytology, and supporting pathology on pleural biopsy. (See <a class="local">'Pleural fluid analysis'</a> above.)</p><p class="headingAnchor" id="H1862161358"><span class="h2">No role for routine steroid use</span><span class="headingEndMark"> — </span>Data are insufficient to support routine adjunctive use of corticosteroids for management of tuberculous pleural effusions [<a href="#rid2">2,72</a>]. Some older studies suggest that administration of corticosteroids may shorten the duration of fever and time to fluid resorption [<a href="#rid73">73,74</a>]. However, no difference in mortality was observed in a randomized trial including more than 190 patients with HIV infection with tuberculous pleural effusion treated with or without a <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> taper (in conjunction with antituberculous therapy) [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H3891590395"><span class="h2">Pleural drainage</span><span class="headingEndMark"> — </span>Therapeutic thoracentesis is reasonable if the effusion is causing dyspnea; otherwise, routine complete drainage of pleural fluid at the time of diagnosis does not appear to affect long-term outcomes [<a href="#rid29">29</a>]. This was demonstrated in a randomized trial including 61 patients with newly diagnosed tuberculous pleural effusion treated with antituberculous therapy with or without catheter drainage [<a href="#rid27">27</a>]. Drainage was associated with more rapid resolution of dyspnea (four versus eight days), although after the first week there were no differences in symptoms between groups during the 24-week follow-up period. Pulmonary function and the degree of residual pleural thickening on chest radiography were the same in both groups at the conclusion of the trial.</p><p>Data are insufficient to support routine use of intrapleural fibrinolytic agents for management of loculated tuberculous effusion. Several studies have demonstrated lower incidence of residual pleural thickening [<a href="#rid76">76-78</a>] and higher lung volumes [<a href="#rid78">78</a>]; however, the role of these agents requires further study by using clinical outcomes. Issues related to their use is discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults"</a>.)</p><p>Patients with tuberculous empyema may require decortication [<a href="#rid79">79</a>]. Issues related to management of empyema are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults"</a>.)</p><p class="headingAnchor" id="H1476569884"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>With appropriate therapy, most patients defervesce within two weeks; in most cases, pleural fluid is resorbed within six weeks. However, some patients take up to two months to defervesce, and fluid resorption may take up to four months.</p><p>Among patients with HIV infection, a paradoxical worsening of signs and symptoms may be observed in the first months following initiation of antiretroviral therapy; this is known as the immune reconstitution inflammatory syndrome. (See  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p class="headingAnchor" id="H4695691"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with tuberculous pleural effusion usually have an acute febrile illness with nonproductive cough and pleuritic chest pain. Night sweats, chills, weakness, dyspnea, and weight loss can also occur. Computed tomography is more sensitive than chest radiography; it demonstrates parenchymal disease in over 80 percent of cases. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of tuberculous pleural effusion should be suspected in patients with pleural effusion and relevant epidemiologic risk factors for tuberculosis (TB) infection (these include prior history of TB infection, known or possible TB exposure, positive test for TB infection (<a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> or interferon-gamma release assay), and/or past or present residence in or travel to an area where TB is endemic). (See <a class="local">'Clinical approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of tuberculous pleural effusion may be definitively established via demonstration of <em>Mycobacterium tuberculosis</em> in pleural fluid or a pleural biopsy specimen. In the setting of high clinical suspicion for TB, a presumptive diagnosis of tuberculous pleural effusion may be established in the setting of pleural fluid analysis with lymphocytic-to-neutrophil ratio &gt;0.75 and adenosine deaminase (ADA) &gt;40 units/L or by demonstration of one or more caseating granulomas on pleural biopsy. (See <a class="local">'Clinical approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thoracentesis is warranted in the following circumstances (see <a class="local">'Clinical approach'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suspected tuberculous pleural effusion in the absence of an established diagnosis of pulmonary TB (via sputum or other studies)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diagnosis of pulmonary TB established (via sputum or other studies) but additional etiology for pleural effusion (such as malignancy) suspected clinically</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pleural fluid should be sent for the following studies: cell count, protein, glucose, pH, lactate dehydrogenase (LDH), acid-fast bacilli (AFB) smear and culture, Gram stain and culture, and ADA level (if the effusion is lymphocyte predominant). Confirmation of the diagnosis of TB requires growth in culture, which may take up to eight weeks. (See <a class="local">'Pleural fluid analysis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pleural biopsy is warranted if the pleural fluid ADA level is &lt;40 units/L and/or pleural fluid evaluation is otherwise not diagnostic. Pleural biopsy should be sent for AFB smear and culture as well as histopathologic evaluation. Histopathology may demonstrate granulomas and/or acid-fast bacilli. The presence of caseating (necrotizing) granulomas on histologic examination is virtually diagnostic of tuberculous pleural effusion. (See <a class="local">'Pleural biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The approach to antituberculous therapy for treatment of tuberculous pleural effusion is the same as the approach to treatment of active pulmonary TB; this is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a> and  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the absence of definitive diagnosis, presumptive antituberculous therapy is warranted for patients with epidemiologic risk factors for TB infection and supportive diagnostic studies in the absence of an alternative diagnosis. (See <a class="local">'Antituberculous therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Therapeutic thoracentesis is reasonable if the effusion is causing dyspnea; otherwise, routine complete drainage of pleural fluid at the time of diagnosis does not appear to affect long-term outcomes. (See <a class="local">'Pleural drainage'</a> above.)</p><p></p><p class="headingAnchor" id="H660741"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Steven Sahn, MD, and Michael Frye, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Zhai K, Lu Y, Shi HZ. Tuberculous pleural effusion. J Thorac Dis 2016; 8:E486.</a></li><li><a class="nounderline abstract_t">Light RW. Update on tuberculous pleural effusion. Respirology 2010; 15:451.</a></li><li><a class="nounderline abstract_t">Baumann MH, Nolan R, Petrini M, et al. Pleural tuberculosis in the United States: incidence and drug resistance. Chest 2007; 131:1125.</a></li><li><a class="nounderline abstract_t">Seibert AF, Haynes J Jr, Middleton R, Bass JB Jr. Tuberculous pleural effusion. Twenty-year experience. Chest 1991; 99:883.</a></li><li><a class="nounderline abstract_t">Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017; 64:e1.</a></li><li><a class="nounderline abstract_t">Gopi A, Madhavan SM, Sharma SK, Sahn SA. Diagnosis and treatment of tuberculous pleural effusion in 2006. Chest 2007; 131:880.</a></li><li><a class="nounderline abstract_t">Torgersen J, Dorman SE, Baruch N, et al. Molecular epidemiology of pleural and other extrapulmonary tuberculosis: a Maryland state review. Clin Infect Dis 2006; 42:1375.</a></li><li><a class="nounderline abstract_t">Kim HJ, Lee HJ, Kwon SY, et al. The prevalence of pulmonary parenchymal tuberculosis in patients with tuberculous pleuritis. Chest 2006; 129:1253.</a></li><li><a class="nounderline abstract_t">Merino JM, Carpintero I, Alvarez T, et al. Tuberculous pleural effusion in children. Chest 1999; 115:26.</a></li><li><a class="nounderline abstract_t">Leibowitz S, Kennedy L, Lessof MH. The tuberculin reaction in the pleural cavity and its suppression by antilymphocyte serum. Br J Exp Pathol 1973; 54:152.</a></li><li><a class="nounderline abstract_t">STEAD WW, EICHENHOLZ A, STAUSS HK. Operative and pathologic findings in twenty-four patients with syndrome of idiopathic pleurisy with effusion, presumably tuberculous. Am Rev Tuberc 1955; 71:473.</a></li><li><a class="nounderline abstract_t">Berger HW, Mejia E. Tuberculous pleurisy. Chest 1973; 63:88.</a></li><li><a class="nounderline abstract_t">Valdés L, Alvarez D, San José E, et al. Tuberculous pleurisy: a study of 254 patients. Arch Intern Med 1998; 158:2017.</a></li><li><a class="nounderline abstract_t">Frye MD, Pozsik CJ, Sahn SA. Tuberculous pleurisy is more common in AIDS than in non-AIDS patients with tuberculosis. Chest 1997; 112:393.</a></li><li><a class="nounderline abstract_t">Tshibwabwa-Tumba E, Mwinga A, Pobee JO, Zumla A. Radiological features of pulmonary tuberculosis in 963 HIV-infected adults at three Central African Hospitals. Clin Radiol 1997; 52:837.</a></li><li><a class="nounderline abstract_t">Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000; 161:1376.</a></li><li><a class="nounderline abstract_t">Sahn SA, Iseman MD. Tuberculous empyema. Semin Respir Infect 1999; 14:82.</a></li><li><a class="nounderline abstract_t">Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340:367.</a></li><li><a class="nounderline abstract_t">Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326:231.</a></li><li><a class="nounderline abstract_t">Kitinya JN, Richter C, Perenboom R, et al. Influence of HIV status on pathological changes in tuberculous pleuritis. Tuber Lung Dis 1994; 75:195.</a></li><li><a class="nounderline abstract_t">Relkin F, Aranda CP, Garay SM, et al. Pleural tuberculosis and HIV infection. Chest 1994; 105:1338.</a></li><li><a class="nounderline abstract_t">Frye MD, Pozsik CJ, Sahn SA. Tuberculous pleuritis and HIV disease. Chest 1995; 108:102S.</a></li><li><a class="nounderline abstract_t">Hulnick DH, Naidich DP, McCauley DI. Pleural tuberculosis evaluated by computed tomography. Radiology 1983; 149:759.</a></li><li><a class="nounderline abstract_t">Shaw JA, Diacon AH, Koegelenberg CFN. Tuberculous pleural effusion. Respirology 2019; 24:962.</a></li><li><a class="nounderline abstract_t">Bagheri R, Haghi SZ, Dalouee MN, et al. Effect of decortication and pleurectomy in chronic empyema patients. Asian Cardiovasc Thorac Ann 2016; 24:245.</a></li><li><a class="nounderline abstract_t">Kumar A, Asaf BB, Lingaraju VC, et al. Thoracoscopic Decortication of Stage III Tuberculous Empyema Is Effective and Safe in Selected Cases. Ann Thorac Surg 2017; 104:1688.</a></li><li><a class="nounderline abstract_t">Lai YF, Chao TY, Wang YH, Lin AS. Pigtail drainage in the treatment of tuberculous pleural effusions: a randomised study. Thorax 2003; 58:149.</a></li><li><a class="nounderline abstract_t">Barbas CS, Cukier A, de Varvalho CR, et al. The relationship between pleural fluid findings and the development of pleural thickening in patients with pleural tuberculosis. Chest 1991; 100:1264.</a></li><li><a class="nounderline abstract_t">Bhuniya S, Arunabha DC, Choudhury S, et al. Role of therapeutic thoracentesis in tuberculous pleural effusion. Ann Thorac Med 2012; 7:215.</a></li><li><a class="nounderline abstract_t">Bolliger CT, de Kock MA. Influence of a fibrothorax on the flow/volume curve. Respiration 1988; 54:197.</a></li><li><a class="nounderline abstract_t">Candela A, Andujar J, Hernández L, et al. Functional sequelae of tuberculous pleurisy in patients correctly treated. Chest 2003; 123:1996.</a></li><li><a class="nounderline abstract_t">de Pablo A, Villena V, Echave-Sustaeta J, Encuentra AL. Are pleural fluid parameters related to the development of residual pleural thickening in tuberculosis? Chest 1997; 112:1293.</a></li><li><a class="nounderline abstract_t">Sahn SA, Huggins JT, San José ME, et al. Can tuberculous pleural effusions be diagnosed by pleural fluid analysis alone? Int J Tuberc Lung Dis 2013; 17:787.</a></li><li><a class="nounderline abstract_t">Jiménez Castro D, Díaz Nuevo G, Pérez-Rodríguez E, Light RW. Diagnostic value of adenosine deaminase in nontuberculous lymphocytic pleural effusions. Eur Respir J 2003; 21:220.</a></li><li><a class="nounderline abstract_t">Riantawan P, Chaowalit P, Wongsangiem M, Rojanaraweewong P. Diagnostic value of pleural fluid adenosine deaminase in tuberculous pleuritis with reference to HIV coinfection and a Bayesian analysis. Chest 1999; 116:97.</a></li><li><a class="nounderline abstract_t">Levine H, Metzger W, Lacera D, Kay L. Diagnosis of tuberculous pleurisy by culture of pleural biopsy specimen. Arch Intern Med 1970; 126:269.</a></li><li><a class="nounderline abstract_t">Epstein DM, Kline LR, Albelda SM, Miller WT. Tuberculous pleural effusions. Chest 1987; 91:106.</a></li><li><a class="nounderline abstract_t">Antony VB, Repine JE, Harada RN, et al. Inflammatory responses in experimental tuberculosis pleurisy. Acta Cytol 1983; 27:355.</a></li><li><a class="nounderline abstract_t">Antony VB, Sahn SA, Antony AC, Repine JE. Bacillus Calmette-Guérin-stimulated neutrophils release chemotaxins for monocytes in rabbit pleural spaces and in vitro. J Clin Invest 1985; 76:1514.</a></li><li class="breakAll">Light RW. Chapter 10. In: Pleural Diseases, 2d ed, Lea &amp; Febiger, Philadelphia 1990.</li><li><a class="nounderline abstract_t">Piras MA, Gakis C, Budroni M, Andreoni G. Adenosine deaminase activity in pleural effusions: an aid to differential diagnosis. Br Med J 1978; 2:1751.</a></li><li><a class="nounderline abstract_t">Ocaña I, Martinez-Vazquez JM, Segura RM, et al. Adenosine deaminase in pleural fluids. Test for diagnosis of tuberculous pleural effusion. Chest 1983; 84:51.</a></li><li><a class="nounderline abstract_t">Valdés L, San José E, Alvarez D, et al. Diagnosis of tuberculous pleurisy using the biologic parameters adenosine deaminase, lysozyme, and interferon gamma. Chest 1993; 103:458.</a></li><li><a class="nounderline abstract_t">Orriols R, Coloma R, Ferrer J, et al. Adenosine deaminase in tuberculous pleural effusion. Chest 1994; 106:1633.</a></li><li><a class="nounderline abstract_t">Bañales JL, Pineda PR, Fitzgerald JM, et al. Adenosine deaminase in the diagnosis of tuberculous pleural effusions. A report of 218 patients and review of the literature. Chest 1991; 99:355.</a></li><li><a class="nounderline abstract_t">Villegas MV, Labrada LA, Saravia NG. Evaluation of polymerase chain reaction, adenosine deaminase, and interferon-gamma in pleural fluid for the differential diagnosis of pleural tuberculosis. Chest 2000; 118:1355.</a></li><li><a class="nounderline abstract_t">Sivakumar P, Marples L, Breen R, Ahmed L. The diagnostic utility of pleural fluid adenosine deaminase for tuberculosis in a low prevalence area. Int J Tuberc Lung Dis 2017; 21:697.</a></li><li><a class="nounderline abstract_t">Lo Cascio CM, Kaul V, Dhooria S, et al. Diagnosis of tuberculous pleural effusions: A review. Respir Med 2021; 188:106607.</a></li><li><a class="nounderline abstract_t">Baba K, Hoosen AA, Langeland N, Dyrhol-Riise AM. Adenosine deaminase activity is a sensitive marker for the diagnosis of tuberculous pleuritis in patients with very low CD4 counts. PLoS One 2008; 3:e2788.</a></li><li><a class="nounderline abstract_t">Aljohaney A, Amjadi K, Alvarez GG. A systematic review of the epidemiology, immunopathogenesis, diagnosis, and treatment of pleural TB in HIV-infected patients. Clin Dev Immunol 2012; 2012:842045.</a></li><li><a class="nounderline abstract_t">Gakis C. Adenosine deaminase in pleural effusions. Chest 1995; 107:1772.</a></li><li><a class="nounderline abstract_t">Heyderman RS, Makunike R, Muza T, et al. Pleural tuberculosis in Harare, Zimbabwe: the relationship between human immunodeficiency virus, CD4 lymphocyte count, granuloma formation and disseminated disease. Trop Med Int Health 1998; 3:14.</a></li><li><a class="nounderline abstract_t">Richter C, Perenboom R, Mtoni I, et al. Clinical features of HIV-seropositive and HIV-seronegative patients with tuberculous pleural effusion in Dar es Salaam, Tanzania. Chest 1994; 106:1471.</a></li><li><a class="nounderline abstract_t">Gil V, Cordero PJ, Greses JV, Soler JJ. Pleural tuberculosis in HIV-infected patients. Chest 1995; 107:1775.</a></li><li><a class="nounderline abstract_t">Trajman A, da Silva Santos Kleiz de Oliveira EF, Bastos ML, et al. Accuracy of polimerase chain reaction for the diagnosis of pleural tuberculosis. Respir Med 2014; 108:918.</a></li><li><a class="nounderline abstract_t">Denkinger CM, Schumacher SG, Boehme CC, et al. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. Eur Respir J 2014; 44:435.</a></li><li><a class="nounderline abstract_t">Hiraki A, Aoe K, Eda R, et al. Comparison of six biological markers for the diagnosis of tuberculous pleuritis. Chest 2004; 125:987.</a></li><li><a class="nounderline abstract_t">Aoe K, Hiraki A, Murakami T, et al. Diagnostic significance of interferon-gamma in tuberculous pleural effusions. Chest 2003; 123:740.</a></li><li><a class="nounderline abstract_t">Wongtim S, Silachamroon U, Ruxrungtham K, et al. Interferon gamma for diagnosing tuberculous pleural effusions. Thorax 1999; 54:921.</a></li><li><a class="nounderline abstract_t">Jiang J, Shi HZ, Liang QL, et al. Diagnostic value of interferon-gamma in tuberculous pleurisy: a metaanalysis. Chest 2007; 131:1133.</a></li><li><a class="nounderline abstract_t">Verea Hernando HR, Masa Jimenez JF, Dominguez Juncal L, et al. Meaning and diagnostic value of determining the lysozyme level of pleural fluid. Chest 1987; 91:342.</a></li><li><a class="nounderline abstract_t">Kirsch CM, Kroe DM, Azzi RL, et al. The optimal number of pleural biopsy specimens for a diagnosis of tuberculous pleurisy. Chest 1997; 112:702.</a></li><li><a class="nounderline abstract_t">Sahn SA. State of the art. The pleura. Am Rev Respir Dis 1988; 138:184.</a></li><li><a class="nounderline abstract_t">Diacon AH, Van de Wal BW, Wyser C, et al. Diagnostic tools in tuberculous pleurisy: a direct comparative study. Eur Respir J 2003; 22:589.</a></li><li><a class="nounderline abstract_t">Emad A, Rezaian GR. Diagnostic value of closed percutaneous pleural biopsy vs pleuroscopy in suspected malignant pleural effusion or tuberculous pleurisy in a region with a high incidence of tuberculosis: a comparative, age-dependent study. Respir Med 1998; 92:488.</a></li><li><a class="nounderline abstract_t">Conde MB, Loivos AC, Rezende VM, et al. Yield of sputum induction in the diagnosis of pleural tuberculosis. Am J Respir Crit Care Med 2003; 167:723.</a></li><li><a class="nounderline abstract_t">Losi M, Bossink A, Codecasa L, et al. Use of a T-cell interferon-gamma release assay for the diagnosis of tuberculous pleurisy. Eur Respir J 2007; 30:1173.</a></li><li><a class="nounderline abstract_t">Aggarwal AN, Agarwal R, Gupta D, et al. Interferon Gamma Release Assays for Diagnosis of Pleural Tuberculosis: a Systematic Review and Meta-Analysis. J Clin Microbiol 2015; 53:2451.</a></li><li><a class="nounderline abstract_t">Wang G, Wang S, Yang X, et al. Accuracy of Xpert MTB/RIF Ultra for the Diagnosis of Pleural TB in a Multicenter Cohort Study. Chest 2020; 157:268.</a></li><li><a class="nounderline abstract_t">Porcel JM, Azzopardi M, Koegelenberg CF, et al. The diagnosis of pleural effusions. Expert Rev Respir Med 2015; 9:801.</a></li><li><a class="nounderline abstract_t">Chopra A, Foulke L, Judson MA. Sarcoidosis associated pleural effusion: Clinical aspects. Respir Med 2022; 191:106723.</a></li><li><a class="nounderline abstract_t">Ryan H, Yoo J, Darsini P. Corticosteroids for tuberculous pleurisy. Cochrane Database Syst Rev 2017; 3:CD001876.</a></li><li><a class="nounderline abstract_t">Lee CH, Wang WJ, Lan RS, et al. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study. Chest 1988; 94:1256.</a></li><li><a class="nounderline abstract_t">Matchaba PT, Volmink J. Steroids for treating tuberculous pleurisy. Cochrane Database Syst Rev 2000; :CD001876.</a></li><li><a class="nounderline abstract_t">Elliott AM, Luzze H, Quigley MA, et al. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis 2004; 190:869.</a></li><li><a class="nounderline abstract_t">Kwak SM, Park CS, Cho JH, et al. The effects of urokinase instillation therapy via percutaneous transthoracic catheter in loculated tuberculous pleural effusion: a randomized prospective study. Yonsei Med J 2004; 45:822.</a></li><li><a class="nounderline abstract_t">Cases Viedma E, Lorenzo Dus MJ, González-Molina A, Sanchis Aldás JL. A study of loculated tuberculous pleural effusions treated with intrapleural urokinase. Respir Med 2006; 100:2037.</a></li><li><a class="nounderline abstract_t">Cao GQ, Li L, Wang YB, et al. Treatment of free-flowing tuberculous pleurisy with intrapleural urokinase. Int J Tuberc Lung Dis 2015; 19:1395.</a></li><li><a class="nounderline abstract_t">Chen B, Zhang J, Ye Z, et al. Outcomes of Video-Assisted Thoracic Surgical Decortication in 274 Patients with Tuberculous Empyema. Ann Thorac Cardiovasc Surg 2015; 21:223.</a></li></ol></div><div id="topicVersionRevision">Topic 8012 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27499981" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Tuberculous pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20345583" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Update on tuberculous pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17426219" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pleural tuberculosis in the United States: incidence and drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1901261" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Tuberculous pleural effusion. Twenty-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27932390" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17356108" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Diagnosis and treatment of tuberculous pleural effusion in 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16619148" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Molecular epidemiology of pleural and other extrapulmonary tuberculosis: a Maryland state review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685016" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The prevalence of pulmonary parenchymal tuberculosis in patients with tuberculous pleuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9925059" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Tuberculous pleural effusion in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4700698" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The tuberculin reaction in the pleural cavity and its suppression by antilymphocyte serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14361964" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Operative and pathologic findings in twenty-four patients with syndrome of idiopathic pleurisy with effusion, presumably tuberculous.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4630686" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Tuberculous pleurisy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9778201" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Tuberculous pleurisy: a study of 254 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9266874" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Tuberculous pleurisy is more common in AIDS than in non-AIDS patients with tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9392461" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Radiological features of pulmonary tuberculosis in 963 HIV-infected adults at three Central African Hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764337" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10197400" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Tuberculous empyema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9929528" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tuberculosis in patients with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1345800" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7919311" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Influence of HIV status on pathological changes in tuberculous pleuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8181315" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pleural tuberculosis and HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Tuberculous pleuritis and HIV disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6647852" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pleural tuberculosis evaluated by computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31418985" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Tuberculous pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26787536" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effect of decortication and pleurectomy in chronic empyema patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28964422" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Thoracoscopic Decortication of Stage III Tuberculous Empyema Is Effective and Safe in Selected Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12554899" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pigtail drainage in the treatment of tuberculous pleural effusions: a randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1935279" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The relationship between pleural fluid findings and the development of pleural thickening in patients with pleural tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23189098" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Role of therapeutic thoracentesis in tuberculous pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3247520" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Influence of a fibrothorax on the flow/volume curve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796180" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Functional sequelae of tuberculous pleurisy in patients correctly treated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9367471" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Are pleural fluid parameters related to the development of residual pleural thickening in tuberculosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23676163" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Can tuberculous pleural effusions be diagnosed by pleural fluid analysis alone?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12608433" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diagnostic value of adenosine deaminase in nontuberculous lymphocytic pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10424510" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Diagnostic value of pleural fluid adenosine deaminase in tuberculous pleuritis with reference to HIV coinfection and a Bayesian analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4988357" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Diagnosis of tuberculous pleurisy by culture of pleural biopsy specimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3792061" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Tuberculous pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6346774" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Inflammatory responses in experimental tuberculosis pleurisy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3902892" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Bacillus Calmette-Guérin-stimulated neutrophils release chemotaxins for monocytes in rabbit pleural spaces and in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3902892" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Bacillus Calmette-Guérin-stimulated neutrophils release chemotaxins for monocytes in rabbit pleural spaces and in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/737480" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Adenosine deaminase activity in pleural effusions: an aid to differential diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6602695" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adenosine deaminase in pleural fluids. Test for diagnosis of tuberculous pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8432137" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Diagnosis of tuberculous pleurisy using the biologic parameters adenosine deaminase, lysozyme, and interferon gamma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7956443" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Adenosine deaminase in tuberculous pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1824928" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Adenosine deaminase in the diagnosis of tuberculous pleural effusions. A report of 218 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083686" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Evaluation of polymerase chain reaction, adenosine deaminase, and interferon-gamma in pleural fluid for the differential diagnosis of pleural tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28482965" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The diagnostic utility of pleural fluid adenosine deaminase for tuberculosis in a low prevalence area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34536698" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Diagnosis of tuberculous pleural effusions: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18665218" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Adenosine deaminase activity is a sensitive marker for the diagnosis of tuberculous pleuritis in patients with very low CD4 counts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22474483" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A systematic review of the epidemiology, immunopathogenesis, diagnosis, and treatment of pleural TB in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7781389" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Adenosine deaminase in pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9484963" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pleural tuberculosis in Harare, Zimbabwe: the relationship between human immunodeficiency virus, CD4 lymphocyte count, granuloma formation and disseminated disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7956405" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical features of HIV-seropositive and HIV-seronegative patients with tuberculous pleural effusion in Dar es Salaam, Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7781394" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pleural tuberculosis in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24803060" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Accuracy of polimerase chain reaction for the diagnosis of pleural tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24696113" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15006958" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparison of six biological markers for the diagnosis of tuberculous pleuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12628872" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Diagnostic significance of interferon-gamma in tuberculous pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10491456" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Interferon gamma for diagnosing tuberculous pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17426220" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Diagnostic value of interferon-gamma in tuberculous pleurisy: a metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3816312" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Meaning and diagnostic value of determining the lysozyme level of pleural fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9315802" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The optimal number of pleural biopsy specimens for a diagnosis of tuberculous pleurisy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3059866" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : State of the art. The pleura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14582908" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Diagnostic tools in tuberculous pleurisy: a direct comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692110" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Diagnostic value of closed percutaneous pleural biopsy vs pleuroscopy in suspected malignant pleural effusion or tuberculous pleurisy in a region with a high incidence of tuberculosis: a comparative, age-dependent study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12598215" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Yield of sputum induction in the diagnosis of pleural tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17715165" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Use of a T-cell interferon-gamma release assay for the diagnosis of tuberculous pleurisy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25994163" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Interferon Gamma Release Assays for Diagnosis of Pleural Tuberculosis: a Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31437432" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Accuracy of Xpert MTB/RIF Ultra for the Diagnosis of Pleural TB in a Multicenter Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26449328" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The diagnosis of pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34954636" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Sarcoidosis associated pleural effusion: Clinical aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28290161" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Corticosteroids for tuberculous pleurisy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3056661" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796669" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Steroids for treating tuberculous pleurisy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15295690" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15515192" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The effects of urokinase instillation therapy via percutaneous transthoracic catheter in loculated tuberculous pleural effusion: a randomized prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16580190" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A study of loculated tuberculous pleural effusions treated with intrapleural urokinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26467594" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Treatment of free-flowing tuberculous pleurisy with intrapleural urokinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25818121" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Outcomes of Video-Assisted Thoracic Surgical Decortication in 274 Patients with Tuberculous Empyema.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
